Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis

Starting soon

Conditions studied: Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

In brief

This study will explore how adults in Japan with pulmonary fibrosis decide whether to continue or discontinue antifibrotic therapy after experiencing antifibrotic therapy-related adverse events.

Key facts

Study ID

NCT07722507

Run by

Bristol-Myers Squibb

People needed

40

Starts

2026-08-01

Expected to finish

2027-05-31

Last updated by the study team

2026-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must meet all the following criteria to be eligible for inclusion in this study:
• Pulmonary fibrosis (PF) participants in Japan. Note: This includes those clinically recognized as having idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF).
• Participants who are ≥18 years of age at the time of providing informed consent via the web-based system.
• Participants receiving outpatient care for pulmonary fibrosis (PF) who have been introduced to this study by a referring physician.
• Participants who have a history of taking, or are currently taking, pirfenidone, nintedanib, or nerandomilast.
• Participants who have experienced at least one antifibrotic (AF) therapy-related adverse event (AE).
• Discontinuation group only
• Participants who have not received AF therapy for at least 1 month prior to enrollment.
• Participants whose AF therapy was discontinued within 6 months prior to enrollment.
• Participants whose reason for discontinuing AF therapy includes at least one AF therapy-related AE.
• Continuation group only
• Participants who feel or have felt burdened by the experienced AE.
• Participants who have continued AF therapy for a specific period (≥6 months) at the time of enrollment.

You may not qualify if…

• Participants meeting any of the following criteria will be excluded from the study:
• <!-- -->
• Participants currently participating in any interventional clinical trials (regardless of the study drug, excluding observational studies).
• Participants who have undergone lung transplantation.
• Discontinuation group only 1) Participants who discontinued AF therapy solely for reasons other than AE (e.g., financial reasons, disease progression).

Where it is running

• Mebix, Inc. — Tokyo, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.